Tag: biosimilar growth hormones market segments

  • Biosimilar Growth Hormones Market Size In 2026: Growth Outlook And Forecast Through 2030

    Biosimilar Growth Hormones Market Size In 2026: Growth Outlook And Forecast Through 2030

    Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

    Biosimilar Growth Hormones Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

    The biosimilar growth hormones market has expanded quickly in recent years. It is projected to rise from $0.89 billion in 2025 to $0.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. The expansion observed in the historic period can be attributed to the high cost of branded growth hormone therapies, increasing prevalence of growth hormone deficiency, rising pediatric growth disorder diagnoses, limited access to affordable treatment options, and dependence on hospital-based administration.

    The biosimilar growth hormones market size is anticipated to expand rapidly over the next few years, projected to reach $1.46 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. The expansion during this forecast period stems from factors such as the patent expiry of branded growth hormones, increased approvals for biosimilars, the proliferation of self-administration therapies, heightened awareness of growth disorders, and escalating healthcare expenditure in developing markets. Notable trends for the forecast period include the growing adoption of economical biosimilar growth hormones, a rising need for pediatric and adult growth hormone treatments, an increasing preference for subcutaneous self-administration, the growth of online pharmacies and specialized clinics, and improved regulatory acceptance for biosimilars.

    Get A Free Sample Report With In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Biosimilar Growth Hormones Market Growth Momentum: What Factors Are Shaping Demand?

    The expansion of the global biosimilar growth hormone market is propelled by the rising incidence of growth hormone deficiency among children. This deficiency arises from damage to the pituitary gland or hypothalamus, potentially stemming from abnormal development before birth (congenital) or issues that emerge during or after birth (acquired). For example, data from September 2023, provided by Hormones Australia through the Endocrine Society of Australia (ESA) – an Australia-based national authority for the treatment of endocrine related conditions and disease – indicates that approximately 2 to 3 out of every 10,000 people are estimated to be affected by growth hormone deficiency. Consequently, the expanding population of children experiencing growth deficiencies is a key factor boosting the biosimilar growth hormones industry.

    Biosimilar Growth Hormones Market Segment Landscape And Growth Outlook

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    Biosimilar Growth Hormones Market Trends Redefining Industry Growth

    Leading companies in the biosimilar growth hormones market are innovating solutions, such as human growth hormone, to enhance the effectiveness and affordability of treatments for growth hormone deficiencies. Growth hormone solutions refer to medical interventions or supplements designed to stimulate or replace human growth hormone (HGH) in the body, addressing growth deficiencies or anti-aging needs. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based healthcare company, obtained US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla). This is a once-weekly injectable human growth hormone treatment specifically developed for pediatric patients experiencing growth hormone deficiency (GHD). This long-acting growth hormone therapy provides an alternative to daily injections, thereby improving adherence and convenience for both patients and caregivers. The approval stemmed from clinical studies that demonstrated its efficacy and safety, signifying a notable progression in growth hormone therapies.

    Biosimilar Growth Hormones Market Competitive Landscape: Who Leads The Industry?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    View The Full Biosimilar Growth Hormones Market Report:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Biosimilar Growth Hormones Market Leading Geography: Which Region Contributes The Most Revenue?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biosimilar Growth Hormones Market Forecast Signals New Revenue Opportunities Through 2030

    Biosimilar Growth Hormones Market Forecast Signals New Revenue Opportunities Through 2030

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Biosimilar Growth Hormones Market Forecast Highlighting Growth From $0.97 Billion To $1.46 Billion

    The biosimilar growth hormones sector has experienced swift expansion in recent years. Its valuation is projected to increase from $0.89 billion in 2025 to $0.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.1%. During the historical period, this growth was driven by several factors, including the elevated costs associated with branded growth hormone treatments, a rising incidence of growth hormone deficiency, an uptick in diagnoses of pediatric growth disorders, restricted availability of cost-effective therapeutic options, and a reliance on hospital-based administration methods.

    The biosimilar growth hormones market is anticipated to experience robust expansion over the coming years, with projections indicating it will reach a value of $1.46 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.5%. This forecasted growth is driven by several factors, including the expiration of patents on branded growth hormones, a rising number of biosimilar approvals, the broadening of self-administration treatment options, greater public awareness of growth disorders, and increased healthcare spending in developing economies. Key developments shaping this period involve a growing shift toward more affordable biosimilar growth hormone products, heightened demand for therapies targeting both pediatric and adult patients, an increased preference for subcutaneous self-administration, the expansion of online pharmacies and specialized clinics, and a more favorable regulatory environment for biosimilars.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Biosimilar Growth Hormones Market Demand Drivers Creating New Revenue Opportunities

    An increasing number of children affected by growth hormone deficiency is fueling the expansion of the global biosimilar growth hormone market. This condition arises from damage to the pituitary gland or hypothalamus, which can be caused either by an abnormal development occurring before birth (congenital) or by events that take place during or after childbirth (acquired). As an example, in September 2023, data from Hormones Australia, published by the Endocrine Society of Australia—a national body focused on managing endocrine conditions and diseases—indicated that growth hormone deficiency is estimated to impact 2 to 3 individuals per 10,000 people. Consequently, the rising prevalence of growth deficiencies among children is propelling growth within the biosimilar growth hormone industry.

    Biosimilar Growth Hormones Market Segment Performance And Strategic Opportunities

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    Biosimilar Growth Hormones Market Trends Driving Strategic Industry Expansion

    Major players in the biosimilar growth hormone market are developing innovative human growth hormone solutions aimed at improving both treatment effectiveness and accessibility for growth hormone deficiencies. These growth hormone solutions encompass medical treatments or supplements designed to stimulate or replace natural human growth hormone (HGH) in the body, addressing growth deficits or anti-aging concerns. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, along with OPKO Health Inc., another US-based healthcare firm, secured approval from the US Food and Drug Administration (FDA) for NGENLA (somatrogon-ghla). This treatment is a once-weekly injectable human growth hormone specifically developed for pediatric patients suffering from growth hormone deficiency (GHD). By providing a long-acting alternative to daily injections, it significantly enhances adherence and convenience for both patients and their caregivers. The approval was informed by clinical trials that confirmed its efficacy and safety, representing a notable milestone in the evolution of growth hormone therapies.

    Biosimilar Growth Hormones Market Key Players: Which Companies Shape Industry Competition?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    Access The Complete Biosimilar Growth Hormones Market Report:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Biosimilar Growth Hormones Market Largest Region: Which Geography Holds The Highest Market Share?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rising Incidence Of Childhood Growth Hormone Deficiency Spurs Global Biosimilar Growth Hormone Market Is Supporting Development Across The Biosimilar Growth Hormones Market

    Rising Incidence Of Childhood Growth Hormone Deficiency Spurs Global Biosimilar Growth Hormone Market Is Supporting Development Across The Biosimilar Growth Hormones Market

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    What Market Value Expansion Is Expected For The Biosimilar Growth Hormones Market Over The Forecast Period?

    The biosimilar growth hormones market has seen considerable expansion in recent years. This market is projected to expand from $0.89 billion in 2025 to $0.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. The increase observed in previous periods can be linked to factors such as the elevated cost of branded growth hormone therapies, the growing incidence of growth hormone deficiency, an uptick in pediatric growth disorder diagnoses, limited accessibility to affordable treatment options, and a reliance on hospital-based administration.

    The biosimilar growth hormones market is projected to experience substantial expansion over the upcoming years, reaching $1.46 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period stems from factors such as the expiration of patents for branded growth hormones, an increase in biosimilar approvals, the wider availability of self-administration treatments, increased understanding of growth disorders, and a rise in healthcare spending across developing markets. Key developments expected during this period involve a greater embrace of affordable biosimilar growth hormones, heightened demand for growth hormone therapies for both children and adults, a growing inclination towards self-administration through subcutaneous methods, the proliferation of online pharmacies and specialized clinics, and enhanced regulatory acceptance of biosimilars.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

    Which Core Factors Are Supporting The Expansion Of The Biosimilar Growth Hormones Market?

    The increasing number of children affected by growth hormone deficiency is driving the expansion of the global biosimilar growth hormone market. This deficiency results from damage to the pituitary gland or hypothalamus, which can be due to an abnormal formation present before birth (congenital) or something that developed during or after birth (acquired). For instance, in September 2023, Hormones Australia by the Endocrine Society of Australia (ESA), an Australia-based national authority for the treatment of endocrine related conditions and disease, reported that growth hormone deficiency is estimated to affect 2 to 3 out of every 10,000 people. As a result, the rising incidence of growth deficiencies in children is fueling the growth of the biosimilar growth hormones industry.

    How Is The Biosimilar Growth Hormones Market Distributed Across Key Segments?

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    Which Trends Are Influencing The Direction Of The Biosimilar Growth Hormones Market?

    Major companies operating in the biosimilar growth hormones market are actively developing novel solutions like human growth hormone to enhance treatment efficacy and affordability for growth hormone deficiencies. Growth hormone solutions denote medical treatments or supplements designed to stimulate or replace human growth hormone (HGH) in the body, addressing growth deficiencies or anti-aging objectives. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, in collaboration with OPKO Health Inc., a US-based healthcare company, obtained US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla). This is a once-weekly injectable human growth hormone treatment developed for pediatric patients with growth hormone deficiency (GHD). This extended-release growth hormone therapy offers a new option compared to daily injections, which can improve adherence and convenience for patients and caregivers. The approval was based on clinical studies demonstrating its efficacy and safety, marking a significant advancement in growth hormone therapies.

    Who Are The Companies Shaping The Biosimilar Growth Hormones Market Landscape?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    Access The Complete Biosimilar Growth Hormones Market Report:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

    Which Geographic Region Represents The Largest Biosimilar Growth Hormones Market Share?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Biosimilar Growth Hormones Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

    Browse Through More Reports Similar to the Global Biosimilar Growth Hormones Market 2026, By The Business Research Company

    Hormonal Contraceptives Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

    Parathyroid Hormones Market Report 2026

    https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

    Biosimilar Hormone Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biosimilar Growth Hormones Market Developments And Opportunities Across 2026–2030

    Biosimilar Growth Hormones Market Developments And Opportunities Across 2026–2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Changes In Market Value Are Expected For The Biosimilar Growth Hormones Market Over The 2026–2030 Period?

    The biosimilar growth hormones market size has seen significant expansion in recent years. It is projected to increase from $0.89 billion in 2025 to $0.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. The historic period’s growth can be attributed to factors such as the high cost of branded growth hormone therapies, the increasing prevalence of growth hormone deficiency, a rise in pediatric growth disorder diagnoses, limited access to affordable treatment options, and a dependence on hospital-based administration.

    The biosimilar growth hormones market is projected for significant expansion in the coming years. This market is anticipated to reach $1.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. This projected growth is driven by several factors including the expiration of patents for branded growth hormones, an increase in biosimilar approvals, the wider availability of self-administration therapies, heightened awareness of growth disorders, and increased healthcare spending in developing regions. Key trends anticipated during this period involve the greater acceptance of affordable biosimilar growth hormones, a surge in demand for both pediatric and adult growth hormone treatments, a rising inclination towards subcutaneous self-administration, the growth of online pharmacies and specialized clinics, and enhanced regulatory approval for biosimilars.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

    What Key Factors Are Shaping The Biosimilar Growth Hormones Market Landscape?

    The expansion of the global biosimilar growth hormone market is significantly influenced by the increasing number of children affected by growth hormone deficiency. This condition arises from damage to either the pituitary gland or hypothalamus, which can be attributed to an abnormal formation present before birth (congenital) or something that developed during or after birth (acquired). For example, in September 2023, Hormones Australia, a source from the Endocrine Society of Australia (ESA) – which serves as an Australia-based national authority for the treatment of endocrine related conditions and disease – reported that growth hormone deficiency is estimated to affect 2 to 3 out of every 10,000 people. Hence, the rising prevalence of growth deficiencies in children acts as a key driver for the biosimilar growth hormones industry.

    How Is The Biosimilar Growth Hormones Market Segmented Across Different Segment Categories?

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    What Trends Are Affecting The Direction Of The Biosimilar Growth Hormones Market?

    Major companies operating in the biosimilar growth hormones market are creating innovative solutions, including human growth hormone, to improve the effectiveness and affordability of treatments for growth hormone deficiencies. Growth hormone solutions refer to medical interventions or supplements designed to stimulate or replace human growth hormone (HGH) in the body, addressing growth deficiencies or anti-aging objectives. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based healthcare company, secured US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla). This product is a once-weekly injectable human growth hormone treatment developed for pediatric patients experiencing growth hormone deficiency (GHD). This extended-release growth hormone therapy provides an alternative to daily injections, which can enhance patient adherence and convenience for both patients and their caregivers. The approval was granted based on clinical studies that established its efficacy and safety, marking a significant advancement in growth hormone therapies.

    Which Organizations Play A Role In The Biosimilar Growth Hormones Market Landscape?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    Get The Full Biosimilar Growth Hormones Market Report:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

    Which Region Represents The Largest Share Of The Biosimilar Growth Hormones Market?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Biosimilar Growth Hormones Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

    Browse Through More Reports Similar to the Global Biosimilar Growth Hormones Market 2026, By The Business Research Company

    Hormonal Contraceptives Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

    Parathyroid Hormones Market Report 2026

    https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

    Biosimilar Hormone Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biosimilar Growth Hormones Market Outlook 2026–2030

    Biosimilar Growth Hormones Market Outlook 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Is The Market Size Of The Biosimilar Growth Hormones Market Expected To Change Between 2026 And 2030?

    The biosimilar growth hormones market has witnessed significant expansion in recent years. Its valuation is anticipated to increase from $0.89 billion in 2025 to $0.98 billion in 2026, progressing at a compound annual growth rate (CAGR) of 10.1%. This historical development can be attributed to the elevated costs associated with branded growth hormone therapies, the rising incidence of growth hormone deficiency, a surge in diagnoses of pediatric growth disorders, limited access to budget-friendly treatment options, and a dependency on administration within hospital settings.

    The biosimilar growth hormones market is anticipated to experience substantial expansion over the coming years, with its valuation projected to reach $1.46 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This growth during the forecast period is primarily driven by factors such as the expiration of patents for branded growth hormones, a rise in approvals for biosimilars, the broadening scope of self-administration therapies, increased public awareness regarding growth disorders, and a surge in healthcare expenditure within emerging markets. Significant trends expected during this period include the increased uptake of cost-effective biosimilar growth hormones, an escalating demand for both pediatric and adult growth hormone treatments, a stronger preference for self-administration through subcutaneous routes, the expansion of online pharmacies and specialized clinics, and enhanced regulatory acceptance of biosimilars.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

    What Drivers Are Expected To Influence The Biosimilar Growth Hormones Market During The Forecast Period?

    The rising number of children affected by growth hormone deficiency is stimulating the expansion of the global biosimilar growth hormone market. This deficiency occurs due to damage to the pituitary gland or hypothalamus, which can be the result of an abnormal formation present at birth (congenital) or an issue that developed during or after birth (acquired). For instance, in September 2023, as per Hormones Australia by the Endocrine Society of Australia (ESA), an Australia-based national authority focused on treating endocrine-related conditions and diseases, growth hormone deficiency is estimated to impact 2 to 3 out of every 10,000 people. Therefore, the growing prevalence of growth deficiencies in children is a key driver for the biosimilar growth hormones industry’s development.

    How Is The Biosimilar Growth Hormones Market Structured Across Different Segments?

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    Which Trends Are Shaping The Future Of The Biosimilar Growth Hormones Market?

    Leading companies operating in the biosimilar growth hormones market are developing innovative solutions, such as human growth hormone, with the aim of boosting treatment efficacy and affordability for those with growth hormone deficiencies. Growth hormone solutions are medical treatments or supplements designed to either stimulate or replace human growth hormone (HGH) in the body, addressing both growth deficiencies and anti-aging needs. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based healthcare company, obtained US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla). This particular product is a once-weekly injectable human growth hormone treatment tailored for pediatric patients diagnosed with growth hormone deficiency (GHD). This long-acting growth hormone therapy provides an alternative to conventional daily injections, which is expected to improve patient adherence and convenience for both patients and caregivers. The approval stemmed from clinical studies that demonstrated its efficacy and safety, marking a notable advancement in growth hormone therapies.

    Which Major Players Dominate The Biosimilar Growth Hormones Market?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    Read the full biosimilar growth hormones market report here:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

    Which Region Is Forecast To Lead The Biosimilar Growth Hormones Market In Terms Of Market Size?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Biosimilar Growth Hormones Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=3391&type=smp

    Browse Through More Reports Similar to the Global Biosimilar Growth Hormones Market 2026, By The Business Research Company

    Hormonal Contraceptives Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

    Parathyroid Hormones Market Report 2026

    https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

    Biosimilar Hormone Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Biosimilar Growth Hormones Market 2026–2030: Forecast Insights for Business Planning

    Global Biosimilar Growth Hormones Market 2026–2030: Forecast Insights for Business Planning

    Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar growth hormones market from 2026–2035 with trusted insights from The Business Research Company

    Starting from its 2026 valuation, what market size is the Biosimilar Growth Hormones Market expected to reach by 2030?

    The biosimilar growth hormones market has witnessed rapid expansion in recent years. This market is set to increase from $0.89 billion in 2025 to $0.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.1%. The expansion observed historically stems from factors such as the significant cost of branded growth hormone treatments, the rising incidence of growth hormone deficiency, an uptick in diagnoses of pediatric growth disorders, restricted access to affordable treatment choices, and the dependence on hospital-based administration.

    The biosimilar growth hormones market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $1.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. This projected growth during the forecast period is primarily driven by factors such as the expiration of patents for branded growth hormones, a rise in biosimilar approvals, the proliferation of self-administration treatment options, increased public understanding of growth disorders, and escalating healthcare spending in developing economies. Key trends anticipated within this period encompass the wider acceptance of affordable biosimilar growth hormones, a heightened need for both pediatric and adult growth hormone treatments, a developing inclination towards subcutaneous self-administration, the broadening reach of online pharmacies and specialized clinics, and enhanced regulatory recognition for biosimilars.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

    What Drivers Are Driving Adoption Within The Biosimilar Growth Hormones Market?

    An increasing incidence of growth hormone deficiency among children is a key factor propelling the expansion of the global biosimilar growth hormone market. This deficiency arises from damage to either the pituitary gland or the hypothalamus, potentially stemming from an atypical development present before birth (congenital) or an event occurring during or after birth (acquired). For example, data released in September 2023 by Hormones Australia, an initiative of the Endocrine Society of Australia (ESA), a national body in Australia focused on endocrine conditions, indicates that growth hormone deficiency is projected to impact 2 to 3 out of every 10,000 individuals. Consequently, the rising population of children affected by growth deficiencies is a significant catalyst for the expansion of the biosimilar growth hormones industry.

    What Segments Are Included Within The Biosimilar Growth Hormones Market?

    The biosimilar growth hormones market covered in this report is segmented –

    1) By Route Of Administration: Subcutaneous, Intramuscular, Oral

    2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications

    3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

    Subsegments:

    1) By Subcutaneous: Self-administration, Professional Administration

    2) By Intramuscular: Pediatric Care, Adult Care

    3) By Oral: Tablets, Capsules

    What Trends Are Projected To Support The Growth Of The Biosimilar Growth Hormones Market?

    Leading firms within the biosimilar growth hormones market are developing new human growth hormone solutions aimed at improving both the effectiveness and cost-efficiency of treatments for growth hormone deficiencies. These solutions encompass medical therapies or supplements intended to either stimulate the body’s natural human growth hormone (HGH) production or replace it, addressing issues like growth deficiencies or anti-aging needs. As an example, in June 2023, the US Food and Drug Administration (FDA) granted approval for NGENLA (somatrogon-ghla) to Pfizer Inc., a pharmaceutical company from the US, and OPKO Health Inc., a US-based healthcare firm. This product is a human growth hormone treatment administered once weekly via injection, specifically created for pediatric patients suffering from growth hormone deficiency (GHD). Such a long-acting therapy provides a substitute for daily injections, thereby potentially enhancing patient and caregiver compliance and ease of use. Its approval stemmed from clinical trials that validated its effectiveness and safety, signifying a notable progression in the field of growth hormone treatments.

    Who Are The Primary Competitors In The Global Biosimilar Growth Hormones Market?

    Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

    Which Global Regions Are Shaping The Competitive Landscape Of The Biosimilar Growth Hormones Market?

    North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Biosimilar Growth Hormones Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=3391&type=smp

    Browse Through More Reports Similar to the Global Biosimilar Growth Hormones Market 2026, By The Business Research Company

    Hormonal Contraceptives Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

    Parathyroid Hormones Market Report 2026

    https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

    Biosimilar Hormone Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model